Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics, Inc. (NASDAQ: MYGN) generates frequent news as a molecular diagnostic testing and precision medicine company. Its announcements often cover financial results, clinical research, product updates, and collaborations that shape how genetic and genomic testing is used in oncology, women’s health, and mental health care.
Investors and clinicians following MYGN news will see regular earnings releases and financial guidance updates, which the company also furnishes on Form 8-K. These updates describe trends in hereditary cancer testing, tumor profiling, prenatal screening, and pharmacogenomics, along with commentary on business performance and strategic priorities.
Scientific and medical conference activity is another major source of news. Myriad Genetics frequently reports new data on tests such as the MyRisk Hereditary Cancer Test, Precise MRD, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, Foresight Carrier Screen, and the GeneSight Psychotropic test. Company communications highlight abstracts and posters at meetings like the San Antonio Breast Cancer Symposium and the National Society of Genetic Counselors Annual Conference.
News items also describe collaborations with partners including SOPHiA GENETICS, Clairity, and MagView, focused on areas such as liquid biopsy companion diagnostics and integrated breast cancer risk assessment platforms. Updates on leadership changes, credit facilities, and conference presentations at investor healthcare events are also part of the MYGN news flow.
This page provides a centralized view of these developments so readers can review Myriad Genetics’ latest financial disclosures, research milestones, product enhancements, and partnership announcements in one place.
Myriad Genetics (NASDAQ: MYGN) said management will attend two investor healthcare conferences in May and June 2026.
Executives will hold 1-to-1 investor meetings at the BofA Securities 2026 Health Care Conference on May 13, 2026, and a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, with a live audio webcast available on the investor site.
Myriad Genetics (NASDAQ: MYGN) reported Q1 2026 revenue of $200.4 million, up 2% year‑over‑year, with gross margin at 68.7%. GAAP net loss was $34.1 million and adjusted EBITDA was $(4.5) million. The company reiterated full‑year 2026 guidance of $860–$880 million revenue and adjusted EBITDA of $37–$49 million. Key operational highlights include a 13% cancer care volume increase, a 15% decline in prenatal revenue, FDA approval of MyChoice CDx as companion diagnostic for Zejula, and the launch of Precise MRD.
Myriad Genetics (NASDAQ: MYGN) released the GeneSight Mental Health Monitor national survey on April 30, 2026. The survey finds patients with depression and/or anxiety report treatment feels "one-size-fits-all" and 88% would feel more confident with a personalized mental health care plan.
Other findings: 41% of medicated patients call treatment one-size-fits-all; 74% of those still finding a medication feel the same; 65% were unaware genetic testing could inform medication decisions.
Myriad Genetics (NASDAQ: MYGN) will release its first quarter 2026 financial results after market close on May 5, 2026, with a conference call and webcast at 4:30 p.m. ET the same day. Investors can join via live webcast on investor.myriad.com or by telephone after registration; an archived webcast will be available following the call.
Myriad Genetics (NASDAQ: MYGN) will present six abstracts, including two podium presentations, at the American Association for Cancer Research Annual Meeting on April 17-22, 2026 in San Diego. Highlights include MONITOR-Breast neoadjuvant ctDNA dynamics and a phase II adjuvant PD-1 trial, plus four poster presentations and a booth exhibit.
The company will showcase its Precise MRD tumor-informed MRD assay, MyRisk Hereditary Cancer Test with RiskScore, Prolaris, MyChoice CDx, and partnership offerings in biopharma development.
Myriad Genetics (NASDAQ: MYGN) announced that Japan's Ministry of Health, Labour and Welfare approved the MyChoice Test as a companion diagnostic for Lynparza (olaparib) in prostate cancer on April 14, 2026. The approval adds tumor-based HRD/BRCA testing access beyond prior breast and ovarian coverage under Japan's NHI.
This expands testing options for patients with metastatic castration-resistant prostate cancer and may increase identification of PARP inhibitor candidates in Japan.
Myriad Genetics (NASDAQ: MYGN) will present four research abstracts at the Society of Gynecologic Oncology Annual Meeting, April 10-13, 2026, in San Juan, Puerto Rico.
Key highlights: Precise MRD data showed post‑adjuvant ctDNA levels were significantly prognostic of ovarian cancer recurrence; three additional studies use the Myriad Collaborative Research Registry™ with de‑identified data from >1.3 million participants. Presentations and posters occur April 11–13; Myriad will exhibit at booth #523.
Myriad Genetics (NASDAQ: MYGN) announced FDA approval of the MyChoice CDx Test as the companion diagnostic for Zejula (niraparib) in advanced ovarian cancer in the United States. The approval is based on final PRIMA trial data and establishes MyChoice CDx as the only FDA-authorized CDx for Zejula.
The test uses next-generation sequencing to assess BRCA1/2 (including large rearrangements) and a tumor genomic instability score (LOH, TAI, LST) to determine HRD status for treatment decisions.
Myriad (NASDAQ: MYGN) launched the Precise MRD tumor-informed circulating tumor DNA (ctDNA) test on March 2, 2026, with a select group of community oncologists for patients with breast cancer.
The assay uses whole-genome sequencing to create personalized tests and enables ultrasensitive ctDNA detection down to one part per million. Myriad plans a broader U.S. commercial rollout later in 2026, with no limit on participating patients in the initial release.
Myriad Genetics (NASDAQ: MYGN) will present six abstracts at ASCO-GU Feb 26-28, 2026 reporting clinical performance for Precise MRD, Prolaris, and MyRisk oncology tests. Key data include ultra-sensitive ctDNA detection (below 100 ppm), a meta-analysis of 14 studies >8,000 patients showing Prolaris prognostic power, and germline testing results across Gleason and NCCN risk groups.
Findings are largely interim or preliminary but indicate potential diagnostic and prognostic value across genitourinary cancers.